$Iovance B_老虎社区_美港股上老虎

Washington89
05-16

$Iovance Biotherapeutics, Inc.(IOVA)$ 领英上可以看到公司在大量聘请欧洲人才，为国际发展做准备，应该后半年能接欧洲病人。医疗结果也会在这个月的ASCO进一步分享。再加上现在股价特别便宜：P/B 0.74，3.6亿现金，5.8亿市值，0债。目标价10$。

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

好东西要一直拿着
·05-16
瑞银分析师戴维·戴（David Dai）将Iovance Biotherapeutics的评级从“买入”下调至“中性”，目标价从17美元降至2美元。该分析师在一份研究报告中告诉投资者，该公司第一季度Amtagvi的销售额低于预期，且其2025财年业绩指引也已下调，这表明Amtagvi的增长速度正在放缓。瑞银认为，增长速度放缓的原因是实施问题以及小型授权治疗中心的启动，这些中心可能受到医院基础设施不足的阻碍。瑞银下调评级的原因在于Amtagvi销售额预期的下调。
回复
1
举报
远离中概股A股股权
·05-16
建议砍仓，
最大问题在于Q1的时候管理层信心满满说维持营收，结果收入和全年大幅度调低，人品有问题。
黑死素瘤打不过其他疗法。
回复
2
举报
好东西要一直拿着
·05-16
目标10块…你看看现在已经很多分析师已经降到4块了，今天还有从18降到2块的
回复
1
举报
好东西要一直拿着
·05-16
发个招聘信息真的就是烟雾弹
回复
点赞
举报
远离中概股A股股权
·05-16
招聘信息有可能是假的
回复
点赞
举报

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":435538054901904,"tweetId":"435538054901904","gmtCreate":1747342188271,"gmtModify":1747342189816,"author":{"id":3495872648664068,"idStr":"3495872648664068","authorId":3495872648664068,"authorIdStr":"3495872648664068","name":"Washington89","avatar":"https://static.tigerbbs.com/c207e38fa1a9a6a175efc215b6ab4953","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":9,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.44%","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://laohu8.com/S/IOVA\">$Iovance Biotherapeutics, Inc.(IOVA)$&nbsp;</a><v-v data-views=\"1\"></v-v> 领英上可以看到公司在大量聘请欧洲人才，为国际发展做准备，应该后半年能接欧洲病人。医疗结果也会在这个月的ASCO进一步分享。再加上现在股价特别便宜：P/B 0.74，3.6亿现金，5.8亿市值，0债。目标价10$。\n </body></html>","htmlText":"<html><head></head><body><a href=\"https://laohu8.com/S/IOVA\">$Iovance Biotherapeutics, Inc.(IOVA)$&nbsp;</a><v-v data-views=\"1\"></v-v> 领英上可以看到公司在大量聘请欧洲人才，为国际发展做准备，应该后半年能接欧洲病人。医疗结果也会在这个月的ASCO进一步分享。再加上现在股价特别便宜：P/B 0.74，3.6亿现金，5.8亿市值，0债。目标价10$。\n </body></html>","text":"$Iovance Biotherapeutics, Inc.(IOVA)$ 领英上可以看到公司在大量聘请欧洲人才，为国际发展做准备，应该后半年能接欧洲病人。医疗结果也会在这个月的ASCO进一步分享。再加上现在股价特别便宜：P/B 0.74，3.6亿现金，5.8亿市值，0债。目标价10$。","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":5,"repostSize":1,"favoriteSize":0,"link":"https://laohu8.com/post/435538054901904","repostId":0,"isVote":1,"tweetType":1,"viewCount":2119,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["IOVA"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":214,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":435676736156496,"commentId":"435676736156496","gmtCreate":1747402708418,"gmtModify":1747402712097,"authorId":3537417120281286,"author":{"id":3537417120281286,"idStr":"3537417120281286","authorId":3537417120281286,"name":"好东西要一直拿着","avatar":"https://static.tigerbbs.com/ed03e24159cdfb1a1cc9e0eb75d70106","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":435538054901904,"objectIdStr":"435538054901904","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"瑞银分析师戴维·戴（David Dai）将Iovance Biotherapeutics的评级从“买入”下调至“中性”，目标价从17美元降至2美元。该分析师在一份研究报告中告诉投资者，该公司第一季度Amtagvi的销售额低于预期，且其2025财年业绩指引也已下调，这表明Amtagvi的增长速度正在放缓。瑞银认为，增长速度放缓的原因是实施问题以及小型授权治疗中心的启动，这些中心可能受到医院基础设施不足的阻碍。瑞银下调评级的原因在于Amtagvi销售额预期的下调。","text":"瑞银分析师戴维·戴（David Dai）将Iovance Biotherapeutics的评级从“买入”下调至“中性”，目标价从17美元降至2美元。该分析师在一份研究报告中告诉投资者，该公司第一季度Amtagvi的销售额低于预期，且其2025财年业绩指引也已下调，这表明Amtagvi的增长速度正在放缓。瑞银认为，增长速度放缓的原因是实施问题以及小型授权治疗中心的启动，这些中心可能受到医院基础设施不足的阻碍。瑞银下调评级的原因在于Amtagvi销售额预期的下调。","html":"瑞银分析师戴维·戴（David Dai）将Iovance Biotherapeutics的评级从“买入”下调至“中性”，目标价从17美元降至2美元。该分析师在一份研究报告中告诉投资者，该公司第一季度Amtagvi的销售额低于预期，且其2025财年业绩指引也已下调，这表明Amtagvi的增长速度正在放缓。瑞银认为，增长速度放缓的原因是实施问题以及小型授权治疗中心的启动，这些中心可能受到医院基础设施不足的阻碍。瑞银下调评级的原因在于Amtagvi销售额预期的下调。","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":435601713578800,"commentId":"435601713578800","gmtCreate":1747357072663,"gmtModify":1747357076453,"authorId":3452505216401608,"author":{"id":3452505216401608,"idStr":"3452505216401608","authorId":3452505216401608,"name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":435538054901904,"objectIdStr":"435538054901904","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"建议砍仓， \n \n最大问题在于Q1的时候管理层信心满满说维持营收，结果收入和全年大幅度调低，人品有问题。 \n \n黑死素瘤打不过其他疗法。","text":"建议砍仓， \n \n最大问题在于Q1的时候管理层信心满满说维持营收，结果收入和全年大幅度调低，人品有问题。 \n \n黑死素瘤打不过其他疗法。","html":"建议砍仓， \n \n最大问题在于Q1的时候管理层信心满满说维持营收，结果收入和全年大幅度调低，人品有问题。 \n \n黑死素瘤打不过其他疗法。","likeSize":2,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":435676686225488,"commentId":"435676686225488","gmtCreate":1747402566687,"gmtModify":1747402570409,"authorId":3537417120281286,"author":{"id":3537417120281286,"idStr":"3537417120281286","authorId":3537417120281286,"name":"好东西要一直拿着","avatar":"https://static.tigerbbs.com/ed03e24159cdfb1a1cc9e0eb75d70106","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":435538054901904,"objectIdStr":"435538054901904","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"目标10块…你看看现在已经很多分析师已经降到4块了，今天还有从18降到2块的","text":"目标10块…你看看现在已经很多分析师已经降到4块了，今天还有从18降到2块的","html":"目标10块…你看看现在已经很多分析师已经降到4块了，今天还有从18降到2块的","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":435647978144528,"commentId":"435647978144528","gmtCreate":1747368365721,"gmtModify":1747368369513,"authorId":3537417120281286,"author":{"id":3537417120281286,"idStr":"3537417120281286","authorId":3537417120281286,"name":"好东西要一直拿着","avatar":"https://static.tigerbbs.com/ed03e24159cdfb1a1cc9e0eb75d70106","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":435538054901904,"objectIdStr":"435538054901904","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"发个招聘信息真的就是烟雾弹","text":"发个招聘信息真的就是烟雾弹","html":"发个招聘信息真的就是烟雾弹","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":435601792938688,"commentId":"435601792938688","gmtCreate":1747357088777,"gmtModify":1747357092544,"authorId":3452505216401608,"author":{"id":3452505216401608,"idStr":"3452505216401608","authorId":3452505216401608,"name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":435538054901904,"objectIdStr":"435538054901904","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"招聘信息有可能是假的","text":"招聘信息有可能是假的","html":"招聘信息有可能是假的","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0}],"hasMoreComment":true,"orderType":2}

评论（5）

热议股票